Cost Effectiveness Debate Now Features The Body Bag Argument
This article was originally published in The Pink Sheet Daily
Executive Summary
Center for Medicine in the Public Interest contends that over five years, 44,000 fewer patients will be alive if ICER's cost-effectiveness calculation for multiple myeloma treatments is adopted.
You may also be interested in...
How To Handle Off-Label Promotion: A Guide From PhRMA And BIO
Industry communication principles offer best practices for combating contrary evidence, refuting third-party comparative effectiveness analyses and sharing real-world evidence addressing health outcomes and costs.
ICER Eyes QALY Ratios, Budget Impacts In Methods Review
Institute for Clinical and Economic Review plans to unveil an updated drug value framework in early 2017.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.